Skip to main content

Articles

37 result(s) for 'yoshiya tanaka' within Arthritis Research & Therapy

Page 1 of 1

  1. To investigate the safety and effectiveness of mepolizumab (MPZ), an anti-interleukin-5 antibody, as remission induction therapy for severe eosinophilic granulomatosis with polyangiitis (EGPA).

    Authors: Masanobu Ueno, Ippei Miyagawa, Takafumi Aritomi, Koichi Kimura, Shigeru Iwata, Kentaro Hanami, Syunsuke Fukuyo, Satoshi Kubo, Yusuke Miyazaki, Shingo Nakayamada and Yoshiya Tanaka
    Citation: Arthritis Research & Therapy 2022 24:159
  2. We explored whether serum cytokines could be used as biomarkers for optimal use of tumor necrosis factor inhibitors (TNF-i) and interleukin (IL)-17 inhibitors (IL-17-i) in patients with psoriatic arthritis (PsA).

    Authors: Ippei Miyagawa, Shingo Nakayamada, Masanobu Ueno, Yusuke Miyazaki, Shigeru Iwata, Satoshi Kubo, Koshiro Sonomoto, Junpei Anan, Naoaki Ohkubo, Yoshino Inoue and Yoshiya Tanaka
    Citation: Arthritis Research & Therapy 2022 24:86
  3. The unmet need in systemic lupus erythematosus (SLE) with the current standard of care is widely recognised, but few studies have quantified this. The recent definition of treat-to-target endpoints and other t...

    Authors: Rangi Kandane-Rathnayake, Worawit Louthrenoo, Alberta Hoi, Shue-Fen Luo, Yeong-Jian J. Wu, Yi-Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, Sandra V. Navarra, Leonid Zamora, Sargunan Sockalingam, Yuan An, Zhanguo Li, Yasuhiro Katsumata, Masayoshi Harigai…
    Citation: Arthritis Research & Therapy 2022 24:70
  4. Treatment of difficult-to-treat rheumatoid arthritis (D2T RA) is one of the greatest unmet needs in rheumatology. This study aims to find out preferable treatment options for a group of D2T RA patients who are...

    Authors: Sae Ochi, Koshiro Sonomoto, Shingo Nakayamada and Yoshiya Tanaka
    Citation: Arthritis Research & Therapy 2022 24:61
  5. The single nucleotide polymorphism (SNP) rs62324212, located in IL21 antisense RNA 1 (IL21-AS1), has been identified as a genetic risk variant associated with systemic lupus erythematosus (SLE). We aimed to pr...

    Authors: He Hao, Shingo Nakayamada, Naoaki Ohkubo, Kaoru Yamagata, Mingzeng Zhang, Yu Shan, Shigeru Iwata, Tong Zhang and Yoshiya Tanaka
    Citation: Arthritis Research & Therapy 2021 23:302
  6. Peficitinib (ASP015K), a novel oral Janus kinase inhibitor, has demonstrated efficacy and safety in the treatment of patients with rheumatoid arthritis (RA). This study evaluated the effect of peficitinib on p...

    Authors: Yoshiya Tanaka, Tsutomu Takeuchi, Hiroyuki Izutsu, Yuichiro Kaneko, Daisuke Kato, Musashi Fukuda, Mitsuhiro Rokuda and Neil M. Schultz
    Citation: Arthritis Research & Therapy 2021 23:221
  7. To estimate the relationship between serum TNFα, IL-6, and serum CZP levels and the clinical response to CZP in RA patients in the TSUBAME study.

    Authors: Yusuke Miyazaki, Kazuhisa Nakano, Shingo Nakayamada, Satoshi Kubo, Shigeru Iwata, Kentaro Hanami, Shunsuke Fukuyo, Ippei Miyagawa, Ayako Yamaguchi, Akio Kawabe, Kazuyoshi Saito and Yoshiya Tanaka
    Citation: Arthritis Research & Therapy 2021 23:154
  8. Mepolizumab (MPZ), an anti-interleukin-5 antibody, is effective for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA). However, its effectiveness has not been adequately evaluated in real-w...

    Authors: Masanobu Ueno, Ippei Miyagawa, Kazuhisa Nakano, Shigeru Iwata, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Yusuke Miyazaki, Akio Kawabe, Hiroko Yoshinari, Shingo Nakayamada and Yoshiya Tanaka
    Citation: Arthritis Research & Therapy 2021 23:86
  9. The objective of the study was to evaluate the efficacy and safety of upadacitinib over 84 weeks in Japanese patients with active rheumatoid arthritis (RA) and an inadequate response to conventional synthetic ...

    Authors: Hideto Kameda, Tsutomu Takeuchi, Kunihiro Yamaoka, Motohiro Oribe, Mitsuhiro Kawano, Masayuki Yokoyama, Aileen L. Pangan, Yuko Konishi, Sebastian Meerwein and Yoshiya Tanaka
    Citation: Arthritis Research & Therapy 2021 23:9
  10. Baricitinib is an oral selective inhibitor of Janus kinase (JAK)1 and JAK2 that has proved effective and well tolerated in the treatment of rheumatoid arthritis (RA) in an extensive programme of clinical studi...

    Authors: Paul Emery, Patrick Durez, Axel J. Hueber, Inmaculada de la Torre, Esbjörn Larsson, Thorsten Holzkämper and Yoshiya Tanaka
    Citation: Arthritis Research & Therapy 2021 23:3
  11. Rheumatoid arthritis (RA) is a chronic, debilitating autoimmune condition characterized by joint synovial inflammation. Current treatments include methotrexate (MTX), biologic agents, and Janus kinase (JAK) in...

    Authors: Tsutomu Takeuchi, Yoshiya Tanaka, Jay Erdman, Yuichiro Kaneko, Masako Saito, Chieri Higashitani, Ronald Smulders and Christopher Lademacher
    Citation: Arthritis Research & Therapy 2020 22:252
  12. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Paul Emery, Yoshiya Tanaka, Tracy Cardillo, Douglas Schlichting, Terence Rooney, Scott Beattie, Cameron Helt and Josef S. Smolen
    Citation: Arthritis Research & Therapy 2020 22:166

    The original article was published in Arthritis Research & Therapy 2020 22:115

  13. An amendment to this paper has been published and can be accessed via the original article.

    Authors: Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Atsushi Kawakami, Yeong-Wook Song, Yi-Hsing Chen, Mitsuhiro Rokuda, Hiroyuki Izutsu, Satoshi Ushijima, Yuichiro Kaneko, Yoshihiro Nakashima, Teruaki Shiomi and Emi Yamada
    Citation: Arthritis Research & Therapy 2020 22:155

    The original article was published in Arthritis Research & Therapy 2020 22:47

  14. B cell depletion by rituximab (RTX) is an effective treatment for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV). However, peripheral B cell phenotypes and the selection criteria f...

    Authors: Yusuke Miyazaki, Shingo Nakayamada, Satoshi Kubo, Yuichi Ishikawa, Maiko Yoshikawa, Kei Sakata, Shigeru Iwata, Ippei Miyagawa, Kazuhisa Nakano and Yoshiya Tanaka
    Citation: Arthritis Research & Therapy 2020 22:141
  15. The effectiveness and safety of biological disease-modifying antirheumatic drugs (bDMARDs) by age group (< 65, 65–74, and ≥ 75 years) are uncertain. We examined retention rates reflecting the effectiveness and...

    Authors: Akio Kawabe, Kazuhisa Nakano, Satoshi Kubo, Takeshi Asakawa and Yoshiya Tanaka
    Citation: Arthritis Research & Therapy 2020 22:136
  16. In clinical practice, temporary interruption of rheumatoid arthritis (RA) therapy is common for various reasons including side effects, non-compliance, or necessity for surgery. To characterize temporary inter...

    Authors: Paul Emery, Yoshiya Tanaka, Tracy Cardillo, Douglas Schlichting, Terence Rooney, Scott Beattie, Cameron Helt and Josef S. Smolen
    Citation: Arthritis Research & Therapy 2020 22:115

    The Correction to this article has been published in Arthritis Research & Therapy 2020 22:166

  17. Relapses frequently occur in giant cell arteritis (GCA), and long-term glucocorticoid therapy is required. The identification of associated factors with poor treatment outcomes is important to decide the treat...

    Authors: Takahiko Sugihara, Hitoshi Hasegawa, Haruhito A. Uchida, Hajime Yoshifuji, Yoshiko Watanabe, Eisuke Amiya, Yasuhiro Maejima, Masanori Konishi, Yohko Murakawa, Noriyoshi Ogawa, Shunsuke Furuta, Yasuhiro Katsumata, Yoshinori Komagata, Taio Naniwa, Takahiro Okazaki, Yoshiya Tanaka…
    Citation: Arthritis Research & Therapy 2020 22:72
  18. Peficitinib (ASP015K), a novel oral Janus kinase inhibitor, has demonstrated efficacy and safety for the treatment of rheumatoid arthritis (RA) in randomized, controlled trials of up to 52 weeks’ duration. How...

    Authors: Tsutomu Takeuchi, Yoshiya Tanaka, Sakae Tanaka, Atsushi Kawakami, Yeong-Wook Song, Yi-Hsing Chen, Mitsuhiro Rokuda, Hiroyuki Izutsu, Satoshi Ushijima, Yuichiro Kaneko, Yoshihiro Nakashima, Teruaki Shiomi and Emi Yamada
    Citation: Arthritis Research & Therapy 2020 22:47

    The Correction to this article has been published in Arthritis Research & Therapy 2020 22:155

  19. With advancement in the treatment options of rheumatoid arthritis (RA), optimising the outcomes of difficult-to-treat patients has become increasingly important in clinical practice. In particular, insensitivi...

    Authors: Sae Ochi, Kazuyoshi Saito, Fumitaka Mizoguchi, Shigeaki Kato and Yoshiya Tanaka
    Citation: Arthritis Research & Therapy 2020 22:41
  20. 14-3-3η is an intracellular protein also detected in the serum and synovial fluid of patients with rheumatoid arthritis (RA). It is closely related to disease activity and anti-cyclic citrullinated peptide ant...

    Authors: Gulzhan Trimova, Kaoru Yamagata, Shigeru Iwata, Shintaro Hirata, Tong Zhang, Fumi Uemura, Minoru Satoh, Norma Biln, Shingo Nakayamada, Walter P. Maksymowych and Yoshiya Tanaka
    Citation: Arthritis Research & Therapy 2020 22:24
  21. Biologic disease-modifying antirheumatic drugs (bDMARDs) are important options for managing rheumatoid arthritis (RA). Once patients achieve disease control, clinicians may consider dose reduction or withdrawa...

    Authors: Yoshiya Tanaka, Josef S. Smolen, Heather Jones, Annette Szumski, Lisa Marshall and Paul Emery
    Citation: Arthritis Research & Therapy 2019 21:164
  22. Tumor necrosis factor (TNF) inhibitors (TNF-i) are effective in the treatment of entero-Behcet’s disease (BD). However, there is no objective tool for assessment of disease activity in entero-BD; therefore, it...

    Authors: Ippei Miyagawa, Kazuhisa Nakano, Shigeru Iwata, Shingo Nakayamada, Kazuyoshi Saito, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Akio Kawabe, Yusuke Miyazaki and Yoshiya Tanaka
    Citation: Arthritis Research & Therapy 2019 21:151
  23. Following publication of the original article [1], the authors reported an error in Table 2.

    Authors: Yoshiya Tanaka, Kazuteru Wada, Yoshinori Takahashi, Owen Hagino, Hubert van Hoogstraten, Neil M. H. Graham and Hideto Kameda
    Citation: Arthritis Research & Therapy 2019 21:99

    The original article was published in Arthritis Research & Therapy 2019 21:79

  24. Sarilumab is a human immunoglobulin G1 anti-interleukin-6 (IL-6) receptor monoclonal antibody that blocks IL-6 from binding to membrane-bound and soluble IL-6 receptor α. This bridging study assessed the effic...

    Authors: Yoshiya Tanaka, Kazuteru Wada, Yoshinori Takahashi, Owen Hagino, Hubert van Hoogstraten, Neil M. H. Graham and Hideto Kameda
    Citation: Arthritis Research & Therapy 2019 21:79

    The Correction to this article has been published in Arthritis Research & Therapy 2019 21:99

  25. Dermatomyositis (DM) with rapidly progressive interstitial lung disease (DM RP-ILD) is a life-threatening condition. Serum cytokine levels are potentially suitable biomarkers for DM RP-ILD. However, the relati...

    Authors: Yuichi Ishikawa, Shigeru Iwata, Kentaro Hanami, Aya Nawata, Mingzeng Zhang, Kaoru Yamagata, Shintaro Hirata, Kei Sakata, Yasuyuki Todoroki, Kazuhisa Nakano, Shingo Nakayamada, Minoru Satoh and Yoshiya Tanaka
    Citation: Arthritis Research & Therapy 2018 20:240
  26. Following the onset of rheumatoid arthritis (RA), patients experience a functional decline caused by various joint symptoms which affects their activities of daily living and can lead to reduced work productiv...

    Authors: Yoshiya Tanaka, Hideto Kameda, Kazuyoshi Saito, Yuko Kaneko, Eiichi Tanaka, Shinsuke Yasuda, Naoto Tamura, Keishi Fujio, Takao Fujii, Toshihisa Kojima, Tatsuhiko Anzai, Chikuma Hamada, Yoshihisa Fujino, Shinya Matsuda and Hitoshi Kohsaka
    Citation: Arthritis Research & Therapy 2018 20:151
  27. Sirukumab, a high-affinity human monoclonal antibody that selectively binds to interleukin-6, has demonstrated efficacy in the treatment of rheumatoid arthritis (RA) in global phase 1 and phase 2 studies. The ...

    Authors: Tsutomu Takeuchi, Hisashi Yamanaka, Masayoshi Harigai, Ryo Tamamura, Yuichi Kato, Yoshifumi Ukyo, Toshikazu Nakano, Benjamin Hsu and Yoshiya Tanaka
    Citation: Arthritis Research & Therapy 2018 20:42
  28. This study was conducted to evaluate the feasibility of long-term adalimumab (ADA) discontinuation after achievement of low disease activity (LDA) in Japanese patients with early rheumatoid arthritis (RA) and ...

    Authors: Yoshiya Tanaka, Hisashi Yamanaka, Naoki Ishiguro, Nobuyuki Miyasaka, Katsuyoshi Kawana, Junko Kimura, Naoki Agata and Tsutomu Takeuchi
    Citation: Arthritis Research & Therapy 2017 19:56
  29. Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Here, tofacitinib safety and efficacy data from a long-term extension study in Japanese patients are presented.

    Authors: Hisashi Yamanaka, Yoshiya Tanaka, Tsutomu Takeuchi, Naonobu Sugiyama, Hirotoshi Yuasa, Shigeyuki Toyoizumi, Yosuke Morishima, Tomohiro Hirose and Samuel Zwillich
    Citation: Arthritis Research & Therapy 2016 18:34
  30. Treat-to-target strategies to achieve low disease activity or clinical remission are key in the treatment of rheumatoid arthritis (RA). 14-3-3η is a joint-derived biomarker that is expressed at significantly h...

    Authors: Shintaro Hirata, Anthony Marotta, Yuan Gui, Kentaro Hanami and Yoshiya Tanaka
    Citation: Arthritis Research & Therapy 2015 17:280
  31. The objective of this study was to directly compare the safety of tocilizumab (TCZ) and TNF inhibitors (TNFIs) in rheumatoid arthritis (RA) patients in clinical practice.

    Authors: Ryoko Sakai, Soo-Kyung Cho, Toshihiro Nanki, Kaori Watanabe, Hayato Yamazaki, Michi Tanaka, Ryuji Koike, Yoshiya Tanaka, Kazuyoshi Saito, Shintaro Hirata, Koichi Amano, Hayato Nagasawa, Takayuki Sumida, Taichi Hayashi, Takahiko Sugihara, Hiroaki Dobashi…
    Citation: Arthritis Research & Therapy 2015 17:74
  32. Pneumocystis pneumonia (PCP) is one of the most prevalent opportunistic infections in patients undergoing immunosuppressive therapy. In this article, we discuss risk factors for PCP development in patients with r...

    Authors: Takayuki Katsuyama, Kazuyoshi Saito, Satoshi Kubo, Masao Nawata and Yoshiya Tanaka
    Citation: Arthritis Research & Therapy 2014 16:R43
  33. Evidences of biologics-free disease control after discontinuing adalimumab (ADA) in rheumatoid arthritis (RA) patients in clinical practice have not been sufficiently investigated. Purpose of this study is to ...

    Authors: Shintaro Hirata, Kazuyoshi Saito, Satoshi Kubo, Shunsuke Fukuyo, Yasushi Mizuno, Shigeru Iwata, Masao Nawata, Norifumi Sawamukai, Kazuhisa Nakano, Kunihiro Yamaoka and Yoshiya Tanaka
    Citation: Arthritis Research & Therapy 2013 15:R135
  34. Anti-TNF therapies have revolutionized the treatment of rheumatoid arthritis (RA), a common systemic autoimmune disease involving destruction of the synovial joints. However, in the practice of rheumatology ap...

    Authors: Wolfgang Hueber, Beren H Tomooka, Franak Batliwalla, Wentian Li, Paul A Monach, Robert J Tibshirani, Ronald F Van Vollenhoven, Jon Lampa, Kazuyoshi Saito, Yoshiya Tanaka, Mark C Genovese, Lars Klareskog, Peter K Gregersen and William H Robinson
    Citation: Arthritis Research & Therapy 2009 11:R76
  35. Rho is a major small GTP-binding protein that is involved in the regulation of various cell functions, including proliferation and cell migration, through activation of multiple signaling molecules in various ...

    Authors: Shingo Nakayamada, Hitoshi Kurose, Kazuyoshi Saito, Akira Mogami and Yoshiya Tanaka
    Citation: Arthritis Research & Therapy 2005 7:R476

Annual Journal Metrics